Bio Medica Laboratories Ltd.
SMEPrice Range
₹132–139
Issue Size
₹ 52 Cr
Lot Size
2000 Shares
Min. Investment
₹ 2,64,000
Financial Summary
(in crores)| Particulars | FY 2024-25 | FY 2023-24 |
|---|---|---|
| Operating Revenue | 3,819.52 | 1,524.94 |
| Other Income | 12.98 | 9.49 |
| Total Income | 3,832.5 | 1,534.43 |
| Total Expenses | 2,282.25 | 961.79 |
| Profit Before Tax | 1,314.27 | 365.04 |
| Total Profit | 979.49 | 249.87 |
Subscription Details
IPO Timeline
IPO Offer Start
21 May 2026
IPO Offer Ends
25 May 2026
Listing Date
29 May 2026
Use of Proceeds
| # | Purpose | Amount (₹ Cr) |
|---|---|---|
| 1 | Repayment of Loan | 65 |
| 2 | Enhancement of its existing production capabilities by setting up of new manufacturing | 285 |
| 3 | General Corporate Purposes | 70.5 |
Promoters
Promoter Shareholding
Pre-IPO
96.84%
Promoter stake
Post-IPO
67.69%
Promoter stake
Offered to Public
37,72,000
shares
Post Share Capital
85,12,909
shares
About the Company
Our Company is engaged in the manufacturing of Pharmaceutical Parenteral Formulations. We manufacturevariety of products, comprising ethical drugs, generic drugs and over the-counter drugs (OTC) in the form ofinjectables namely Liquid Injections and Dry Powder Injections. These injectables are available in both singledose and multi dose forms, catering both human and veterinary needs. Our products address a wide range ofmedical needs and preferences.
Use of Proceeds
1. To meet out the Repayment of Loan;2. Enhancement of its existing production capabilities by setting up of new manufacturing facility at theexisting premises3. To meet out the General Corporate Purposes